Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents. RESEARCH DESIGN AND METHODS: After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m2) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose <100 mg/dL (<5.6 mmol/L) up to a maximum dose of 60 units/day. The primary outcome was change in HbA1c levels at 30 weeks. RESULTS: HbA1c decreased from 8.5% (69 mmol/mol) to 8.1% (65 mmol/mol) during the run-in period. After randomization, iGlarLixi showed greater reductions in HbA1c from baseline compared with iGlar (–1.1% vs. –0.6%, P < 0.0001), reaching a mean final HbA1c of 6.9% (52 mmol/mol) compared with 7.5% (58 mmol/mol) for iGlar. HbA1c <7.0% (53 mmol/mol) was achieved in 55% of iGlarLixi patients compared with 30% on iGlar. Mean body weight decreased by 0.7 kg with iGlarLixi and increased by 0.7 kg with iGlar (1.4 kg difference, P < 0.0001). Documented symptomatic hypoglycemia (≤70 mg/dL) was comparable between groups. Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi. CONCLUSIONS: Compared with iGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xedratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant improvements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216 -220).”
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“mitigate the weight gain observed with insulin therapy (4,6–9); GLP-1 RAs do, however, present a risk of gastrointestinal adverse events (AEs), leading to frequent discontinuations (10).”
BackgroundSelf-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Basal Insulin Therapy in Type 2 Diabetes
Rosenstock, J., Schwartz, S. L., Clark, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.631 · Cited by 478 · cited 1×
“Basal insulin therapy improves fasting plasma glucose (FPG) and nocturnal hypoglycemia (3), whereas GLP-1 RAs, especially the short-acting compounds, have a significant effect on postprandial plasma glucose (PPG) (4–9).”
BackgroundSelf-citationAmerican Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-er09 · Cited by 379
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288 · cited 1×
“treatment, generally in the 25–30% range (7,9,12).”
Self-citationMeier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Self-citationSeino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Self-citationRiddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Self-citationLingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220 · cited 1×
“combination of insulin degludec and the GLP-1 RA liraglutide (17).”
Background
Research works printed but not linked: 2
- Aroda, 2016, Efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination vs. insulin glargine in patients with T2DM: the LixiLan-L Trial, Diabetes Care, 65, A62
- Sikirica, 2015, Reasons for discontinuation of GLP-1 receptor antagonists: data from a large cross-sectional survey of physicians and type 2 diabetic patients (Abstract), Diabetes Care, 64, A297
Cited by
Items 101–200 of 258
Frias, P. F., & Frías, J. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0926-8 · Cited by 15
Aroda, V. R., Arulandu, J. R., & Cannon, A. J. (2018) · Clinical Diabetes · doi:10.2337/cd17-0065 · Cited by 13
“In contrast, there were no significant differences in hypoglycemia between the co-formulation and basal insulin in the two trials in which the basal insulin dose was capped (DUAL II and LixiLan-L), although the rate was numerically lower with iGlarLixi than with insulin glargine (Table 3) (47,50).”
BackgroundMethodResultInfluentialSelf-citationMcCrimmon, R. J., Falla, E., Sha, J. Z., Alsaleh, A. J. O., Lew, E., Hudson, R. D. A., Baxter, M., & PALMER, K. D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01159-y · Cited by 15
Østergaard, L., Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1313109 · Cited by 14
“Until today, only few studies have been published on efficacy and safety of iGlarLixi, which is recommended to be injected about 1 h before the largest meal [41,42].”
BackgroundNiemoeller, E., Souhami, E., Wu, Y., & Jensen, K. H. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0336-6 · Cited by 13
Self-citationHome, P. D., Aroda, V. R., Blonde, L., Guyot, P., Shaunik, A., Fazeli, M. S., Goswami, H. H., Kalra, S., & Pourrahmat, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14136 · Cited by 14
Self-citationKaneto, H., Koshida, R., & Baxter, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14095 · Cited by 12
“Overall, these efficacy and safety findings are consistent with those from the equivalent global trials (LixiLan-O and LixiLan-L) of iGlarLixi 2 U:1 μg and 3 U:1 mg, in which final mean insulin doses (week 30) were more than double those in the Japanese studies.(58,59)”
ResultFerrannini, E., Niemoeller, E., DEX, T. A., Servera, S., & Mari, A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14688 · Cited by 12
“Combinations of GLP-1RA with basal insulin as separate injectables have been shown to be effective,(3-5) and fixed-ratio combinations of basal insulin plus GLP-1RAs clearly represent a practical advantage to facilitate management.(6,7) The recent LixiLan-G trial (NCT02787551) showed that the titratable fixed-ratio com…”
BackgroundSelf-citationMorea, N., Retnakaran, R. R., Vidal, J., Aroda, V. R., Liu, M., Saremi, A., & Giorgino, F. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14077 · Cited by 12
“The clinical efficacy and safety of iGlarLixi have been established in the LixiLan-L study, 9 which showed greater reduction in HbA1c levels at week 30 with iGlarLixi than with iGlar in patients with T2D inadequately treated with basal insulin.”
Self-citationBlumer, I. R., Pettus, J., & Cavaiola, T. S. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1450058 · Cited by 11
The past decade in type 2 diabetes and future challenges
HADDAD, J. A., & Haddad, A. N. (2018) · HORMONES · doi:10.1007/s42000-018-0080-y · Cited by 11
Pöhlmann, J., Montagnoli, R., Lastoria, G., Parekh, W., Markert, M., & Hunt, B. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s218746 · Cited by 11
“In the network developed by Evans et al to assess the relative efficacy of IDegLira versus iGlarLixi, the anchor treatment was IGlar U100, which was linked to IDegLira via the DUAL V trial and to iGlarLixi via the LixiLan-L trial.(8,10,15) In addition, the DUAL II (IDegLira versus IDeg) and SWITCH 2 (IGlar U100 versus…”
BackgroundMethodHandelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
Sheng, L., Deng, M., Li, X., Wan, H. Y., Lei, C., Prabahar, K., Hernández‐Wolters, B., & Kord‐Varkaneh, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111617 · Cited by 13
Hassanein, M. M., Malek, R., Sifri, S. A., Sahay, R. K., Büyükbeşe, M. A., Djaballah, K., Melas‐Melt, L., & Shaltout, I. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01642-2 · Cited by 12
Horváth, L., Novodvorský, P., & Haluzík, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16645 · Cited by 10
Home, P. D., Mehta, R., Hafidh, K., Gurova, O. Y., Alvarez, A., Serafini, P. R., & Pourrahmat, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14518 · Cited by 9
“Furthermore, bias could have arisen from use of last observation carried forward for missing data because of early termination in certain studies, whereas two studies used statistical modelling instead.(3,4)”
BackgroundMethodResultInfluentialHaluzík, M., Seufert, J., Guja, C., Bonnemaire, M., Bigot, G., Tournay, M., Kis, J. T., & Freemantle, N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01375-8 · Cited by 11
“Indeed, the efficacy and safety of iGlarLixi has been consistently demonstrated in several large randomised controlled trials (RCTs) conducted in individuals with inadequately controlled T2DM, including the LixiLan clinical programme, consisting of LixiLan-O [7], LixiLan-L [8], and LixiLan-G [9], and more recently the…”
MethodInfluentialGiorgino, F., Shaunik, A., Liu, M., & Saremi, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13857 · Cited by 9
“gov), a 30-week trial in patients with type 2 diabetes previously uncontrolled on basal insulin with or without oral antidiabetic drugs (OADs), iGlarLixi showed superior reductions in HbA1c levels and a beneficial effect on body weight compared with iGlar alone.(11) This post hoc analysis of the LixiLan-L trial invest…”
BackgroundMethodLisco, G., Tullio, A. D., Guastamacchia, E., & Triggiani, V. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200705211224 · Cited by 13
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
SKOLNIK, N., Prato, S. D., Blonde, L., Galstyan, G. R., & Rosenstock, J. (2021) · Advances in Therapy · doi:10.1007/s12325-020-01614-5 · Cited by 10
Self-citationPrato, S. D., Frías, J. P., Blonde, L., Aroda, V. R., Shehadeh, N., Saremi, A., DEX, T. A., Niemoeller, E., Souhami, E., Liu, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14068 · Cited by 10
Self-citationHaluzík, M., Taybani, Z. J., Araszkiewicz, A., Cerghizan, A., Mankovsky, B., Zuhdi, A., & Malecki, M. T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01610-w · Cited by 12
“…with other regimens, iGlarLixi provided greater reductions in HbA1c and improved glycaemic control, with a similar risk of hypoglycaemia and more favourable effect on body weight compared with Gla-100 and fewer gastrointestinal adverse events (AEs) compared with lixisenatide alone [19, 20, 23].”
BackgroundMethodValencia, W. M., Florez, H. J., & Palacio, A. M. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00706-4 · Cited by 10
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzík, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 13
Guja, C., Giorgino, F., Blonde, L., Ali, A., Prázný, M., Meier, J. J., Souhami, E., LUBWAMA, R. N., Ji, C. F., & Rosenstock, J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01180-1 · Cited by 9
Self-citationMiyoshi, H., Matsuhisa, M., Yabe, D., Takahashi, Y., Morimoto, Y., & Terauchi, Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01373-w · Cited by 8
Nomoto, H. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.188 · Cited by 9
iGlarLixi for type 2 diabetes: a systematic review and meta-analysis
Liu, Y., Li, C., Li, X., Yang, J., Zheng, Y., Li, F., & Wang, X. (2024) · Endocrine · doi:10.1007/s12020-024-03868-3 · Cited by 8
Haluzík, M., Cypryk, K., Alvarez, A., Lauand, F., Bakıner, O., & Lim, S. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16276 · Cited by 8
“8,10 In the SoliMix study, HbA1c was reduced by 1.3% in participants with T2D inadequately controlled with basal insulin switching to iGlarLixi.”
InfluentialTreatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
Inoue, M., Lorenz, M., Muto, H., Wesch, R., & Hashimoto, Y. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13757 · Cited by 8
“The phase III studies LixiLan-L and LixiLan-O investigated the efficacy and safety of iGlarLixi versus therapy with either lixisenatide or insulin glargine; results indicate that the combination product is both effective and safe in people with T2DM.7,8 In Japan, the product has been modified to a 1:1 combination (1 u…”
BackgroundInfluentialDurable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Blonde, L., Rosenstock, J., Frías, J. P., Birkenfeld, A. L., Niemoeller, E., Souhami, E., Ji, C. F., Prato, S. D., & Aroda, V. R. (2021) · Diabetes Care · doi:10.2337/dc20-2023 · Cited by 8
Self-citationKawaguchi, Y., Miyamoto, S., Hajika, Y., Ashida, N., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13677 · Cited by 8
Shao, H., Alsaleh, A. J. O., DEX, T. A., Lew, E., & Fonseca, V. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01300-5 · Cited by 10
“For baseline values that were not collected in the SoliMix trial, population averages based on published literature [16] or data from the Lixilan-L trial [21] were used.”
MethodHome, P., McCrimmon, R. J., Rosenstock, J., Blüher, M., Pegelow, K., Melas‐Melt, L., Djaballah, K., Giorgino, F., & the SoliMix trial investigators (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14907 · Cited by 7
Self-citationRisović, I., Dumanovic, M. S., Bojić, M., & Djekic, D. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01282-w · Cited by 10
“Clinical trial data from patients receiving fixed-ratio combination showed a weight change of − 0,3 to − 0,7 kg for iGlarLixi and − 2 to − 2,7 kg for iDegLira [12, 13, 16, 17, 24].”
BackgroundGuja, C., Kis, J. T., Haluzík, M., Bonnemaire, M., Bigot, G., Tournay, M., Freemantle, N., & Seufert, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15027 · Cited by 8
“Corresponding to real-life clinical practice, no forced titration of iGlarLixi was followed in the two pooled studies.11,12 This may have contributed to the lower final mean dose of iGlar observed in this analysis (33.3 U/d at week 24) compared with the LixiLan RCTs (39.8 and 46.7 U/d at week 30 in LixiLan-O and LixiL…”
ResultInfluentialTran, E. (2017) · Clinical Diabetes · doi:10.2337/cd17-0037 · Cited by 8
“At the end of the study periods, mean daily doses of iGlarLixi were ~40–50 units (3,4) and mean daily doses of IDegLira were ~30–45 units (5–9).”
BackgroundSKOLNIK, N., Hinnen, D., Kiriakov, Y., MAGWIRE, M. L., & White, J. R. (2018) · Clinical Diabetes · doi:10.2337/cd17-0048 · Cited by 9
“54 units/kg) for insulin-experienced patients (33,34).”
BackgroundMethodInfluentialCowart, K., & Carris, N. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16502 · Cited by 7
Guo, X., Yang, W., Zhang, J., Dong, X., Liu, M. R., Gu, S., Lauand, F., Li, L., Huang, Q., Kang, L., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15074 · Cited by 9
Self-citationTerauchi, Y., Yabe, D., Kaneto, H., Amano, A., Baxter, M., Watanabe, D., Watada, H., & Inagaki, N. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14139 · Cited by 6
Cowart, K., Gonzalez, R. V. L., & Carris, N. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14579 · Cited by 7
Bellido, D., Galiana, P. A., Palomar, J. M. R., Sintes, R. A., Nubiolae, A., Bellido, V., & Romero, G. Z. (2018) · Current Therapeutic Research · doi:10.1016/j.curtheres.2018.09.001 · Cited by 7
Self-citationWali, A. F., Rangraze, I. R., Khan, S. S., Mufti, U., El‐Tanani, M., & Rizzo, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736380 · Cited by 7
Frías, J. P., Ratzki‐Leewing, A. A., DEX, T. A., Meneghini, L., Rodrigues, A., & Shah, V. N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16214 · Cited by 6
Monnier, L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30031-7 · Cited by 6
Zisman, A., DEX, T. A., Roberts, M., Saremi, A., Chao, J., & Aroda, V. R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0507-0 · Cited by 7
Self-citationFrías, J. P., Lorenz, M., Roberts, M., DEX, T. A., Schmider, W., Hurst, W., & SKOLNIK, N. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541316 · Cited by 6
Blonde, L., Berard, L., Saremi, A., Huang, Y., Aroda, V. R., & Raccah, D. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00797-y · Cited by 7
“As previously reported [7], severe symptomatic hypoglycaemic events were rare (five events in the overall iGlarLixi group vs.”
BackgroundResultSelf-citationYoshikawa, F., Uchino, H., Nagashima, T., Usui, S., Miyagi, M., Ando, Y., Kumashiro, N., & Hirose, T. (2021) · Diabetology International · doi:10.1007/s13340-021-00513-6 · Cited by 7
McCrimmon, R. J., PALMER, K. D., Alsaleh, A. J. O., Lew, E., & Puttanna, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01267-3 · Cited by 7
“, lipid parameters), data were extracted from the LixiLan-L trial and applied as a proxy for the population of interest [18].”
MethodGhosh, S. K., Unnikrishnan, A. G., Saboo, B., Kesavadev, J., Aravind, S. R., Bajaj, S., Rajput, R., Seshadri, K., Verma, N., Gupta, A., et al. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.045 · Cited by 7
Kroopnick, J. M., & Davis, S. N. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2089021 · Cited by 6
Jiang, Y., Liu, R., Xuan, J., Lin, S., Zheng, Q., & Pang, J. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01255-w · Cited by 7
Đekić, D., Bojić, M., Janež, A., Majanović, S. K., Hadžimušović, I. G., Ković, T., & Mihalevska, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01407-3 · Cited by 6
“1 mmol/L in LixiLan-G) [9, 10] and in a real-world study (2.”
BackgroundNovodvorský, P., Thieme, L., Laňková, I., Franková, Š., Veselá, A., Záhumenský, E., Edelsberger, T., Löblová, M., Žižka, O., Vytasil, M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70362 · Cited by 5
Préparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Novodvorský, P., Thieme, L., Laňková, I., Mráz, M., Taybani, Z. J., Bótyik, B., Stella, P., Vytasil, M., Lauand, F., Bonnemaire, M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01582-x · Cited by 7
“The expected standard deviation (SD) for the 6-month change from baseline in HbA 1C is 0.9% based on the Lixilan-L trial results [13].”
MethodInfluentialBolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16616 · Cited by 6
“18,31,41 These differences between lixisenatide and liraglutide observed in free combinations with BI 18 are understandably carried over in the respective FRCs with BI.”
InfluentialMalik, R. A., Anderson, J., Russo, G. T., Amani, M. E. A., Adaş, M., Alvarez, A., Lauand, F., Li, X., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16591 · Cited by 5
“12,21 iGlarLixi has also demonstrated superior glycaemic control and body weight benefit in comparison with premixed insulin regimens in the SoliMix RCT. 22 This is further supported by the single-arm Soli-SWITCH study, which demonstrated improved glycaemic outcomes, body weight benefit and a low…”
InfluentialIizuka, K., Baxter, M., Watanabe, D., & Yabe, D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14537 · Cited by 5
“In the randomized LixiLan-L trial, the effects of iGlarLixi on residual hyperglycaemia were compared with those of insulin glargine (iGlar) in people whose T2D was uncontrolled despite treatment with OADs plus basal insulin.(7,8) After 30 weeks of treatment, residual hyperglycaemia was significantly less frequent in p…”
Vargas‐Uricoechea, H., Frías, J. P., & Vargas-Sierra, H. D. (2023) · The Review of Diabetic Studies · doi:10.1900/rds.2023.19.14 · Cited by 10
“iGlarLixi was also superior to BIAsp 30 for body weight change SoliMix trial, participants with suboptimally controlled BI–treated T2DM were evaluated [26-34].”
MethodMalik, R. A., Hwu, C., Jammah, A. A., Arteaga-Díaz, J. M., Djaballah, K., Pilorget, V., Alvarez, A., Vera, C., & Vikulova, O. K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15599 · Cited by 7
Seufert, J., Freemantle, N., Guja, C., Haluzík, M., Tournay, M., Vera, C., Bonnemaire, M., & Kis, J. T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15609 · Cited by 5
Blumer, I. R., Novak, L. M., Edelman, S. V., & Cavaiola, T. S. (2019) · Clinical Diabetes · doi:10.2337/cd18-0102 · Cited by 5
“FRC therapies that contain both a basal insulin and a GLP-1 receptor agonist have been shown to improve glycemic control with a risk of hypoglycemia that is similar to that associated with the use of basal insulin alone (4,5).”
BackgroundMethodResultInfluentialInsulin glargine/lixisenatide in type 2 diabetes: a profile of its use
Deeks, E. D. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00670-4 · Cited by 5
Yabe, D., Iizuka, K., Baxter, M., Watanabe, D., & Kaneto, H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13563 · Cited by 4
Sugimoto, D. H., DEX, T. A., Stager, W., & Aroda, V. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13438 · Cited by 4
“This post-hoc analysis included patient-level data from the LixiLan-L and LixiLan-O trials.(5,6) The LixiLan-L trial enroled patients with T2D who were uncontrolled by use of basal insulin with or without OADs.”
MethodSelf-citationAntsiferov, M. B., Demidov, N. A. D., Balberova, M. A., Safronova, T. I., Mishra, O. A. M., & Magomedova, S. G. (2022) · Diabetes Mellitus · doi:10.14341/dm12809 · Cited by 7
McCarty, D. J., Olenik, A., & McCarty, B. P. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018764984 · Cited by 4
“Aroda and colleagues examined the efficacy of IGlarLixi compared to IGlar in patients with T2DM uncontrolled on basal insulin therapy with or without oral AHAs.(20) Following a 6-week run-in phase, 736 participants with HbA1c levels between 7% and 10%, FPG 140 mg/dL, and IGlar doses between 20 and 50 units were random…”
BackgroundMethodInfluentialMcCrimmon, R. J., Home, P., CHENG, A. Y. Y., Giorgino, F., Fonseca, V. A., Souhami, E., Alvarez, A., Picard, P., & Rosenstock, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14825 · Cited by 3
Self-citationHRAMIAK, I. M., Gerstein, H. C., Leiter, L. A., Yale, J., BAJAJ, H. S., Stewart, J. A., Toutounji, M.-J., & Harris, S. B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14787 · Cited by 3
Khattab, M. A., Khalil, S. H. A., Bassyouni, A., Fawzy, F., Elgayar, A. H., Elebrashy, I., Elhadidy, K. E., Abdallah, K., El-Hefnawy, M. H., Halawa, M. R., et al. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03091-7 · Cited by 5
“Where insulin is required, GLP-1 RA + basal insulin (free combination) or fixed-ratio combinations (insulin glargine/ lixisenatide; insulin degludec/liraglutide) can improve glycemia with less weight gain and without increasing hypoglycemia versus basal insulin alone [36, 37].”
Lauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.005 · Cited by 4
Jammah, A. A., Roushdy, N., Gamil, M., Diab, N. A., Abdelmonaem, N., Safarini, S., Gadallah, M., Zaid, N. A., Shihadeh, Y., Saeed, M., et al. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100164 · Cited by 3
Open questions on basal insulin therapy in T2D: a Delphi consensus
Delphi Board, Alberto, A., Roberto, A., Angelo, A., Baggiore, C., cesare, B., Bonadonna, R. C., Giuseppe, C. S. M., Andrea, D. P., Lorenzo, D. C., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02285-2 · Cited by 3
“…agreed also on the benefits of an intensification approach by adding GLP-1 RA to BI, in fixed or free combination, with the advantages of the extra-glycemic benefits of GLP-1 RA, as documented by several studies, such as the Get-Goal [41, 42], Lixilan [43–45] and Dual [46–50] clinical programs.”
BackgroundHassanein, M. M., Naggar, A. E., Alsheikh, A., Djaballah, K., Saeed, M., Melas‐Melt, L., & Alsifri, S. N. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111567 · Cited by 3
Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.03.023 · Cited by 5
Mu, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15857 · Cited by 3
Haluzík, M., Al‐Sofiani, M. E., CHENG, A. Y. Y., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15811 · Cited by 4
Self-citationKis, J. T., Seufert, J., Haluzík, M., Bonnemaire, M., Vera, C., Tournay, M., Freemantle, N., & Guja, C. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01644-0 · Cited by 4
Harreiter, J., Kosi‐Trebotic, L., Lukas, A., Wolf, P. S., Winhofer, Y., Luger, A., Kautzky‐Willer, A., & Krebs, M. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0249-4 · Cited by 3
“This small study corroborates recent findings of randomized controlled trials (RCTs) investigating the effects and safety of various combinations of once-daily Lixi with either iGlar compared to iGlar alone on top of metformin, or basal insulin compared to metformin and basal insulin, oral agents, or compared to place…”
ResultSKOLNIK, N., Dupree, R. S., & Johnson, E. L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1359518 · Cited by 3
TRAUTMANN, M. E., & Vora, J. P. (2018) · Diabetic Medicine · doi:10.1111/dme.13610 · Cited by 3
Schmider, W., Belder, R., Lee, M., Niemoeller, E., Souhami, E., & Frías, J. P. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1558852 · Cited by 3
Self-citationDAILEY, G. E., BAJAJ, H. S., DEX, T. A., Groleau, M., Stager, W., & Vinik, A. I. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000581 · Cited by 3
González-Gálvez, G., Díaz-Toscano, M. L., Llamas-Moreno, J. F., Fernández-Rodarte, K., & Sañudo‐Maury, M. E. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.020 · Cited by 3
Self-citationXie, P., He, X., Gao, X., Shuai, M., Schmider, W., Jiang, A., Yang, N., & Shi, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01434-0 · Cited by 2
Frechtel, G. D., Sauque‐Reyna, L., Choza‐Romero, R., Anguiano, L., Melas‐Melt, L., & Sañudo‐Maury, M. E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15125 · Cited by 2
“In previous studies, iGlarLixi has been shown to provide improved glycaemic control while attenuating insulin-related body weight gain and having a similar risk of hypoglycaemia versus iGlar alone.(14,15) A meta-analysis of randomized controlled trials comparing basal insulin with twice-daily or thrice-daily premix in…”
BackgroundResultKwiendacz, H., Nabrdalik, K., Czupryniak, L., Klupa, T., Malecki, M. T., Myśliwiec, M., Strojek, K., & Gumprecht, J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02567-1 · Cited by 2
Munshi, M. N., Ritzel, R. A., Jude, E. B., DEX, T. A., Melas‐Melt, L., & Rosenstock, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15377 · Cited by 2
Self-citationGiorgino, F., Guja, C., Aydın, H., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111604 · Cited by 2
Self-citationThe User’s Guide to the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Butalia, S., BAJAJ, H. S., Jain, R., Leung, K., Mansell, K. D., Reichert, S. M., Senior, P. A., & Shah, B. R. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.003 · Cited by 4
Umpierrez, G. E., Gill, J., Hood, D. A., Li, X., & Núñez, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16075 · Cited by 3
Seufert, J., Wiesner, T., Pegelow, K., Kenzler, J., & Pfohl, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16161 · Cited by 3
Li, J., Wang, X., Wu, J., Geng, D., Li, F., Liu, Y., & Shen, Y. (2025) · Endocrine · doi:10.1007/s12020-025-04207-w · Cited by 2
Davidson, J. A., Desouza, C. V., Fonseca, V. A., Frías, J. P., Gaal, L. V., Giorgino, F., Chao, J., DEX, T. A., Roberts, M., Saremi, A., et al. (2019) · Diabetic Medicine · doi:10.1111/dme.14094 · Cited by 2
Blonde, L., Bailey, T. S., Chao, J., DEX, T. A., Frías, J. P., Meneghini, L., Roberts, M., & Aroda, V. R. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01033-1 · Cited by 2
Self-citation
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., Bergenstal, R. M., & on behalf of the LixiLan-L Trial Investigators
- Affiliations
- MedStar Health Research Institute (US)
- Dallas Diabetes Research Center (US)
- Rockwood Clinic (US)
- Catalina Research Institute (US)
- Universidade da Coruña (ES)
- Universidad de Guadalajara (MX)
- Sanofi (Japan) (JP)
- Biostatistics, BMD Consulting Inc., Somerset, NJ
- Sanofi (Germany) (DE)
- Sanofi (France) (FR)
- Park Nicollet Health Services (US)
- Corresponding author
- Aroda, Vanita R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-09-20
- Volume
- 39
- Issue
- 11
- Pages
- 1972-1980
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2521422828
- Cited by
- 260
- References
- 16
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 24 · 2023: 23 · 2022: 24 · 2021: 27 · 2020: 28 · 2019: 26 · 2018: 46 · 2017: 28
- FWCI
- 33.47
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-06-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, lixisenatide, basal insulin, type 2 diabetes, glycemic control, HbA1c, metformin, GLP-1 receptor agonists, weight change, hypoglycemia, gastrointestinal adverse effects, inadequate glycemic control
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Insulin Glargine, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Combinations, Drug Evaluation, Preclinical, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Peptides, Body Mass Index, Treatment Outcome, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.